Preclinical Results

• B7-H6/CD3 T-cell engager induced dose-dependent lysis of CRC cell lines with EC₅₀ values ranging from 0.9 to 25 ng/mL

• In contrast, the viability of B7-H6–negative cells was not affected, demonstrating the selectivity of B7-H6/CD3 T-cell engager

In vitro efficacy of B7-H6/CD3 TCE in CRC cell lines

Zoom

• In vivo, single doses of B7-H6/CD3 TCE reduced tumor volume in CRC cell line–derived xenograft model. The anti-tumor activity was enhanced with continued dosing 

• Moreover, treatment with B7-H6/CD3 TCE led to infiltration and activation of T cells in the tumor tissue resulting in tumor cell death and conversion of a non-inflamed (“cold”) tumor into an inflamed (“hot”) tumor

In vivo efficacy of B7-H6/CD3 TCE in CRC cell line–derived xenograft model

Zoom